Need help finding what you are looking for?
Contact Us
PUBLISHER: FirstWord Group | PRODUCT CODE: 1128146
PUBLISHER: FirstWord Group | PRODUCT CODE: 1128146
Crohn's Disease - KOL Insight
PUBLISHED:
PAGES:
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
KOLs are impressed with the efficacy of AbbVie's Skyrizi but what challenges do they identify that could limit its use and progress in the treatment algorithm? In the oral sphingosine modulator sector, how do experts assess the competing merits of BMS' Zeposia and Pfizer's etrasimod and what factors will influence prescribing? KOLs critically assess the prospects of launched and pipeline therapies.
In addition to the full report, licensed users have access to the Report Highlights slidedeck and the following KOL Bulletins via the Attachments area.
Table of Contents
Executive Summary (1)
Future treatment algorithm
Research objectives (303)
- Marketed drugs (178)
- TNF inhibitors (Remicade, Humira, Cimzia) (55)
- Entyvio (vedolizumab; Takeda) (43)
- Stelara (ustekinumab; Johnson & Johnson) (39)
- Tysabri (natalizumab; Biogen) (14)
- Skyrizi (risankizumab; AbbVie) (27)
- Pipeline drugs (124)
- Tremfya (guselkumab; Janssen Biotech) (19)
- Mirikizumab (Eli Lilly) (16)
- Brazikumab (AstraZeneca) (13)
- Rinvoq (upadacitinib; AbbVie) (38)
- Jyseleca (filgotinib; Galapagos/Gilead Sciences) (16)
- Zeposia (ozanimod; Bristol Myers Squibb) (18)
- Etrasimod (Pfizer) (4)
Future treatment trends (24)
- Key insights summary (24)
- Future treatment strategies for Crohn's disease could see JAK inhibitors, p19s move up to first or second line (24)
Appendix
- KOL details
- KOLs from North America
- KOLs from Europe
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.